Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the upcoming release of its financial results for Q1 2022 on May 9, 2022, after market close. The senior management team will conduct a conference call and webcast at 4:30 PM ET to discuss these results and update investors on corporate progress. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, including a diverse pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors. More details on the call can be found on their investor relations website.

Positive

• Development of multiple RAS(ON) Inhibitors targeting various oncogenic RAS variants.
• Ongoing clinical trials for RAS Companion Inhibitors.
• Strong focus on RAS-addicted cancers with a robust R&D pipeline.

Negative

• None.

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Conference Call and Webcast Information:

• Dial-in: (833) 423-0425 (U.S.) or + 1 (918) 922-3069 (international); conference ID 6994747.
• Live webcast with slides can be accessed at: https://ir.revmed.com/events-and-presentations.

A replay of the webcast will be available on the company’s website shortly after the conference call concludes at https://ir.revmed.com/events-and-presentations and will be archived there for at least 14 days.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS^MULTI), RMC-6291(KRAS^G12C), RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When will Revolution Medicines report its financial results for Q1 2022?

Revolution Medicines will report its financial results for Q1 2022 on May 9, 2022, after market close.

What time will the conference call for Revolution Medicines' Q1 results take place?

The conference call for Revolution Medicines' Q1 results will take place at 4:30 PM ET on May 9, 2022.

How can I access the webcast for Revolution Medicines' Q1 financial results?

The webcast can be accessed at https://ir.revmed.com/events-and-presentations.

What is the focus of Revolution Medicines' R&D pipeline?

Revolution Medicines is focused on developing novel targeted therapies for RAS-addicted cancers, including RAS(ON) Inhibitors and RAS Companion Inhibitors.